# Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

> **NCT04404283** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 239 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04404283
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-20
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-12-31
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404283, "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04404283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*